Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Antimicrobial Agents and Chemotherapy
G G ZhanelDaryl J Hoban

Abstract

A total of 6,991 unique patient isolates of Streptococcus pneumoniae were collected from October 1997 to June 2002 from 25 medical centers in 9 of the 10 Canadian provinces. Among these isolates, 20.2% were penicillin nonsusceptible, with 14.6% being penicillin intermediate (MIC, 0.12 to 1 microg/ml) and 5.6% being penicillin resistant (MIC, > or =2 microg/ml). The proportion of high-level penicillin-resistant S. pneumoniae isolates increased from 2.4 to 13.8% over the last 3 years of the study, and the proportion of multidrug-resistant S. pneumoniae isolates increased from 2.7 to 8.8% over the 5-year period. Resistant rates (intermediate and resistant) among non-beta-lactam agents were as follows: macrolides, 9.6 to 9.9%; clindamycin, 3.8%; doxycycline, 5.5%; chloramphenicol, 3.9%; and trimethoprim-sulfamethoxazole, 19.0%. Rates of resistance to non-beta-lactam agents were higher among penicillin-resistant strains than among penicillin-susceptible strains. No resistance to vancomycin or linezolid was observed; however, 0.1% intermediate resistance to quinupristin-dalfopristin was observed. The rate of macrolide resistance (intermediate and resistant) increased from 7.9 to 11.1% over the 5 years. For the fluoroquinolones, the o...Continue Reading

References

Oct 5, 1978·The New England Journal of Medicine·M R JacobsR Austrian
Apr 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Musher
Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P C Appelbaum
Jan 1, 1992·The Journal of Pediatrics·M A Del BeccaroT L Stull
Jul 1, 1990·The Journal of Antimicrobial Chemotherapy·L J Chalkley, H J Koornhof
Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C G DowsonB G Spratt
Oct 1, 1996·Antimicrobial Agents and Chemotherapy·X S PanL M Fisher
Mar 8, 1997·Lancet·J Giesecke, H Fredlund
Jun 13, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J G BartlettT M File
May 1, 1999·The Journal of Antimicrobial Chemotherapy·A L BarryP C Fuchs
Aug 18, 1999·The American Journal of Medicine·P Ball
Jan 3, 2001·The New England Journal of Medicine·C G WhitneyUNKNOWN Active Bacterial Core Surveillance Program of the Emerging Infections Program Network
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D J HobanR N Jones
Oct 26, 2001·JAMA : the Journal of the American Medical Association·T B HydeUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network

❮ Previous
Next ❯

Citations

Jul 4, 2006·Indian Journal of Pediatrics·Hossam Al-TatariBasim Asmar
Oct 26, 2012·Interdisciplinary Perspectives on Infectious Diseases·Axel Dalhoff
Mar 29, 2006·Current Allergy and Asthma Reports·Aleksandra K WierzbowskiGeorge G Zhanel
Apr 23, 2013·The Journal of Antimicrobial Chemotherapy·Heather J AdamUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)
Aug 24, 2013·The Journal of Antimicrobial Chemotherapy·Aleksandra K WierzbowskiUNKNOWN Canadian Antimicrobial Resistance Alliance
Apr 26, 2005·Current Infectious Disease Reports·Aleksandra K WierzbowskiGeorge G Zhanel
Jul 29, 2011·European Journal of Clinical Pharmacology·Yusuke TanigawaraHisatsugu Tsuda
Jun 23, 2004·Emerging Infectious Diseases·Eva MelanderHåkan Ringberg
Jun 29, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary V DoernSusan Beekmann
Aug 5, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gary A Noskin
Dec 22, 2006·Expert Review of Anti-infective Therapy·James A HadleyRoger M Echols
Jan 31, 2006·Expert Review of Anti-infective Therapy·George G ZhanelDaryl J Hoban
Aug 28, 2013·Expert Review of Anti-infective Therapy·Xianding DengDylan R Pillai
Nov 26, 2005·Expert Review of Anti-infective Therapy·Stephen H Zinner
Jan 19, 2008·Expert Opinion on Pharmacotherapy·Javier AspaFelipe Rodríguez de Castro
Jan 12, 2016·Expert Opinion on Drug Metabolism & Toxicology·Kristin E LinderMichael D Nailor
Apr 14, 2011·Expert Opinion on Emerging Drugs·Vicenç FalcóJordi Rello
Mar 7, 2008·Expert Opinion on Investigational Drugs·Margaret R Hammerschlag, Roopali Sharma
May 25, 2004·Expert Opinion on Pharmacotherapy·Joseph M Blondeau, Bayan Missaghi
Jul 3, 2007·Current Medical Research and Opinion·Gopal KrishnaZaiqi Wang
May 4, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Mensa, A Trilla
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xianding DengDylan R Pillai
Jun 30, 2009·International Journal of Antimicrobial Agents·James A KarlowskyGeorge G Zhanel
Apr 29, 2008·The Veterinary Journal·Luis J CastroJuan J García
May 29, 2007·Diagnostic Microbiology and Infectious Disease·Ross J DavidsonKevin R Forward
Nov 23, 2006·The Medical Clinics of North America·Gary V Doern
Jun 17, 2011·International Journal of Clinical Practice·J A Bosso, R H Drew
Nov 24, 2004·International Journal of Antimicrobial Agents·George G ZhanelJames A Karlowsky
Sep 14, 2004·The American Journal of Medicine·Michael R Jacobs
Aug 4, 2004·International Journal of Antimicrobial Agents·Marek RzeszutekGeorge G Zhanel
Jun 15, 2004·International Journal of Antimicrobial Agents·P C AppelbaumG S Tillotson
Aug 1, 2006·The Journal of Infection·Adam P Fraise
Apr 22, 2006·Diagnostic Microbiology and Infectious Disease·Linda P DiPersioLinda A DeFine
Apr 25, 2006·Diagnostic Microbiology and Infectious Disease·Kwan Soo KoNam Yong Lee
Apr 2, 2005·Clinics in Chest Medicine·Cheryl M Weyers, Kenneth V Leeper
Aug 17, 2004·Infectious Disease Clinics of North America·Maria Joyce, Christopher W Woods
Jun 5, 2004·Clinics in Laboratory Medicine·Bülent Bozdogan, Peter C Appelbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.